ın Esquibel
Ì

## **AGENCY BILL ANALYSIS - 2025 REGULAR SESSION**

		ERAL INFORMATION an original bill, amendment,		<sup>f</sup> a previous bill <sub>j</sub>	!			
Date Prepared: 1/31/2025			Check all that apply:					
Bill Number:		SB 193	Or	iginal <u>x</u>	ginal x Co			
			Amen	lment	Sı	ubstitute		
O'Mall Angel N		licaelita Debbie ey, Michael Padilla, M. Charley, Antoinette Lopez	Agency Name and Code Number:					
			Person Writing					
Short Weight Title: Coverage		Loss Drugs Insurance	•		Christa Street			
		ge	Phone: 505-9°					
ECTION II:	FISC	CAL IMPACT	Email:	cstreet@r		ov		
ECTION II:		APPROPRIA	ΓΙΟΝ (dollars in tho	ısands)		ov		
		APPROPRIAT	ΓΙΟΝ (dollars in tho	usands) urring	ımdoj.g	Fund		
		APPROPRIA	ΓΙΟΝ (dollars in tho	ısands)	ımdoj.g			
FY	Y25	APPROPRIAT	ΓΙΟΝ (dollars in tho	usands) urring	ımdoj.g	Fund		
FY	Y25	APPROPRIATE Appropriation FY2  expenditure decreases)	ΓΙΟΝ (dollars in tho	urring recurring	ımdoj.g	Fund		
FY	Y25	APPROPRIATE Appropriation FY2  expenditure decreases)	ΓΙΟΝ (dollars in thousant)  Recor Non  E (dollars in thousan	urring recurring  ds)	ring	Fund		
FY	Y25	APPROPRIATE Appropriation  FYZ  expenditure decreases)  REVENUE	ΓΙΟΝ (dollars in thousant)  Recor Non  E (dollars in thousan	urring recurring ds)	ring	Fund Affected		

(Parenthesis ( ) indicate revenue decreases)

## **ESTIMATED ADDITIONAL OPERATING BUDGET IMPACT (dollars in thousands)**

	FY25	FY26	FY27	3 Year Total Cost	Recurring or Nonrecurri ng	Fund Affected
Total						

(Parenthesis ( ) Indicate Expenditure Decreases)

Duplicates/Conflicts with/Companion to/Relates to: Duplicates/Relates to Appropriation in the General Appropriation Act

## **SECTION III: NARRATIVE**

This analysis is neither a formal Opinion nor an Advisory Letter issued by the New Mexico Department of Justice. This is a staff analysis in response to a committee or legislator's request. The analysis does not represent any official policy or legal position of the NM Department of Justice.

## **BILL SUMMARY**

Synopsis:

SB 193 would require certain health insurance plans, policies, and contracts to provide coverage for injectable glucagon-like peptide-1 receptor agonist (GLP-1 agonist) medication prescribed for chronic weight management in adults with obesity.

Section 1 of the Act would add a new section to the Health Care Purchasing Act. *See* NMSA 1978, Chapter 13, Article 7. Under the new section, group health coverage, including any form of self-insurance that is offered, issued, or renewed under the Health Care Purchasing Act that provides coverage for prescription drugs, would be required to provide coverage for at least one GLP-1 agonist proscribed for chronic weight management in adults with obesity.

Section 2 of the Act would add a new section to Chapter 59A, Article 22 of the NMSA. Article 22 of the Insurance Code (Chapter 59A) governs health insurance contracts. Section 2 of the Act would require individual or group health insurance plans to provide coverage for at least one GLP-1 agonist proscribed for chronic weight management in adults with obesity.

Section 3 of the Act would add a new section to NMSA 1978 Chapter 59A, Article 23. Article 23 governs Group and Blanket Health Insurance Contracts. Section 3 would require a group or blanket insurance policy, health care plan, or certificate of health insurance that is delivered, issued for delivery, or renewed in New Mexico that provides coverage for prescription drugs to provide coverage for at least one injectable GLP-1 agonist prescribed for chronic weight management in adults with obesity.

Section 4 of the Act would add a new section to the Health Maintenance Organization Law. See NMSA 1978, §§ 59A-46-1 to -72. Section 4 would require an individual or group health maintenance contract that is delivered, issued for delivery, or renewed in New Mexico that provides coverage for prescription drugs to provide coverage for at least one injectable GLP-1 agonist prescribed for chronic weight management in adults with obesity.

Section 5 of the Act would add a new section to the Nonprofit Health Care Plan Law. See NMSA 1978, §§ 59A-47-1 to – 66. Section 5 would require an individual or group health care plan that is delivered, issued for delivery, or renewed in New Mexico that provides coverage for prescription drugs to provide coverage for at least one injectable GLP-1 agonist prescribed for

chronic weight management in adults with obesity. Section 6 of the Act provides that the provisions of the Act apply to all health insurance policies, plans, and contracts that become effective on or after January 1, 2026. FISCAL IMPLICATIONS N/A **SIGNIFICANT ISSUES** None. PERFORMANCE IMPLICATIONS None. **ADMINISTRATIVE IMPLICATIONS** None. CONFLICT, DUPLICATION, COMPANIONSHIP, RELATIONSHIP None. **TECHNICAL ISSUES** None. **OTHER SUBSTANTIVE ISSUES'** None. **ALTERNATIVES** None. WHAT WILL BE THE CONSEQUENCES OF NOT ENACTING THIS BILL Status quo.

**AMENDMENTS** 

None.